Table 1. Baseline clinical characteristics and correlation analysis of CTCs in patients with LUAD (n=5,128).

Characteristic	Value	Correlation coefficient	P
Gender		0.101	0.21
Male	1,902 (37.09)
Female	3,226 (62.91)
Age (years)	59.96±9.88	−0.001	>0.99
Underlying diseases
Hypertension	891 (17.38)	0.125	0.12
Diabetes	928 (18.10)	0.034	0.67
Coronary heart disease	32 (6.24)	0.074	0.36
Active smoker	1,581 (30.83)	−0.057	0.48
Radiological features
Tumor size (mm)	23.35±12.35	0.151	0.058
Tumor lobation	2,774 (54.10)	0.680	0.043*
Air bronchogram	291 (5.67)	0.712	0.03*
Location
RUL	1,965 (38.32)	0.064	0.43
RML	417 (8.13)	0.085	0.29
RLL	736 (14.35)	0.095	0.24
LUL	1252 (24.41)	−0.052	0.52
LLL	758 (14.78)	0.018	0.83
Density (HU)	−186.95±258.89	0.099	0.21
Spiculated margin	3,677 (71.70)	0.000	>0.99
Vacuole sign	435 (8.49)	−0.013	0.87
Pleural indentation	1,613 (31.45)	−0.039	0.63
Necrosis	359 (7.00)	0.032	0.70
Vascular wall invasion	548 (10.69)	−0.092	0.25
Pleural infiltration	1,032 (20.12)	−0.011	0.89
Perineural invasion	129 (2.52)	−0.002	0.98
Intravascular tumor thrombus	1,354 (26.40)	−0.041	0.61
Positive incision margin	8 (0.16)	−0.021	0.83
Positive lymph node	1,161 (22.64)	−0.090	0.26
Genetic mutation
EGFR-mutated	2,588 (50.47)	0.634	0.047*
ALK-mutated	297 (5.79)	0.150	0.06
ROS1-mutated	748 (14.59)	0.155	0.052
KRAS-mutated	672 (13.10)	0.148	0.06
BRAF-mutated	309 (6.03)	0.132	0.10

Data are presented as n (%), or mean ± standard deviation. *, P<0.05. CTC, circulating tumor cell; LUAD, lung adenocarcinoma; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; HU, Hounsfield unit; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog; BRAF, v-Raf murine sarcoma viral oncogene homolog B.